Thrombosis and Embolism during Pregnancy and the Puerperium: Acute Management

Scope

This guideline addresses the immediate investigation and treatment of suspected acute VTE (DVT or PE) in pregnancy and the puerperium. Risk-based prevention is covered separately in GTG No. 37a (thromboprophylaxis).

Principle: Treat First, Confirm Second

If DVT or PE is clinically suspected, anticoagulant treatment with LMWH should be started immediately, before objective testing confirms the diagnosis, unless treatment is strongly contraindicated. Diagnosis should still be pursued expeditiously. Every maternity unit should have an agreed local protocol for objective diagnosis of suspected VTE.

Diagnostic Pathway — Suspected DVT

• Compression duplex ultrasound is the primary diagnostic test where DVT is clinically suspected.
• If ultrasound confirms DVT, anticoagulant treatment is continued.
• If ultrasound is negative but clinical suspicion remains high, anticoagulation should continue and the test repeated (serial compression ultrasonography has good sensitivity for proximal DVT).

Diagnostic Pathway — Suspected PE

1. Chest X-ray (CXR) and ECG should be performed in all women with suspected PE — CXR can identify alternative pathology (e.g. pneumonia, pneumothorax) and a normal CXR improves the interpretability of a subsequent V/Q scan.
2. If DVT symptoms/signs are also present, perform compression duplex ultrasound first — a confirmed DVT indirectly confirms PE (anticoagulant management is the same either way), potentially avoiding chest irradiation.
3. If no DVT symptoms/signs, proceed to definitive lung imaging: either a ventilation/perfusion (V/Q) scan or a CT pulmonary angiogram (CTPA).
   • If the CXR is abnormal and PE is clinically suspected, CTPA is preferred over V/Q.
   • Choice between V/Q and CTPA otherwise depends on local availability and an agreed local protocol; women should be involved in this decision.
   • CTPA carries a higher (though still low) maternal breast radiation dose and a small excess lifetime breast cancer risk; V/Q scanning (perfusion-only in pregnancy) delivers a slightly higher fetal radiation dose but lower maternal breast dose. Both carry acceptably low fetal risk.
4. Repeat or alternative testing is required if the initial V/Q scan or CTPA is normal but clinical suspicion remains high.
5. D-dimer testing should NOT be used to investigate suspected acute VTE in pregnancy — it is physiologically elevated in normal pregnancy and does not reliably exclude VTE. A pre-test clinical probability (Wells-type) scoring approach also has no proven role in this context per the guideline.
6. Thrombophilia screening should not be performed before starting treatment.

Acute Treatment

• LMWH is first-line for confirmed or strongly suspected DVT/PE.
• Dosing approach: therapeutic-dose LMWH is titrated against the woman's booking or early-pregnancy weight, not current weight. There is insufficient evidence to mandate once-daily versus twice-daily dosing — both are acceptable per local protocol, and practice has shifted toward once-daily regimens in many units.
• Routine anti-Xa monitoring is not required except at extremes of body weight or with complicating factors (e.g. renal impairment, recurrent VTE); routine platelet monitoring is not needed with LMWH (only with unfractionated heparin postoperatively).
• Compression stockings and leg elevation are used adjunctively for DVT to reduce oedema; early mobilisation with stockings is encouraged.
• Warfarin should not be used antenatally — it crosses the placenta and is teratogenic/fetotoxic.

Massive/Life-Threatening PE

• Collapsed or shocked women require immediate assessment by a senior multidisciplinary team (obstetrician, physician, radiologist).
• Intravenous unfractionated heparin — not LMWH — is the preferred initial treatment where there is cardiovascular compromise, because it is rapidly reversible and easily titrated.
• Urgent echocardiogram or CTPA within 1 hour of presentation should be arranged; if massive PE is confirmed (or, in extremis, before confirmation), thrombolysis should be considered. Thoracotomy/surgical embolectomy is an option managed on an individualised basis.
• A temporary inferior vena cava (IVC) filter may be considered peripartum for iliac vein VTE, or for proven DVT with recurrent PE despite adequate anticoagulation.

Anticoagulation Duration and Delivery Planning

• Therapeutic anticoagulation continues for the remainder of the pregnancy and at least 6 weeks postnatally, for a total treatment duration of at least 3 months.
• Around planned delivery: LMWH maintenance should be stopped 24 hours before elective caesarean section or induction of labour; once in established spontaneous labour, women should not inject further LMWH.
• Regional anaesthesia/analgesia should be delayed at least 24 hours after the last therapeutic LMWH dose; LMWH should not be given for at least 4 hours after spinal or epidural siting/removal.
• Postnatally, women choose between continuing LMWH or switching to an oral anticoagulant (warfarin) — warfarin should not be started until at least day 5 postpartum.
• Neither LMWH, unfractionated heparin, nor warfarin is a contraindication to breastfeeding.

High-Yield Exam Points

• Treat first, test second: start LMWH on clinical suspicion of DVT/PE and continue until objectively excluded — do not wait for imaging.
• D-dimer is not used to diagnose or exclude VTE in pregnancy (physiologically raised); thrombophilia screening is not done pre-treatment.
• Compression duplex ultrasound is first-line for suspected DVT and, if positive with concurrent PE symptoms, avoids the need for chest imaging.
• For suspected PE: CXR + ECG first; CTPA is preferred over V/Q when the CXR is abnormal; otherwise choice is protocol/availability-dependent.
• LMWH dosing is weight-based on booking/early-pregnancy weight (not current weight); once- or twice-daily dosing are both acceptable.
• Massive PE with cardiovascular compromise → IV unfractionated heparin (not LMWH) is first-line; thrombolysis considered if confirmed or peri-arrest.
• Minimum total anticoagulation duration is 3 months, continuing to at least 6 weeks postpartum.
• Stop LMWH 24 hours before planned delivery/regional anaesthesia; resume per local protocol postnatally.
• Warfarin is contraindicated antenatally (teratogenic) but safe in breastfeeding, alongside heparins.

Source: RCOG Green-top Guideline No. 37b (April 2015 (third edition; first published April 2001 as GTG No. 28, second edition Feb 2007/reviewed 2010). No published RCOG update since 2015 as of this writing — clinicians should cross-check against current national VTE guidance for any interim changes.)

Read the original on rcog.org.uk

Clinically reviewed by NHS obstetricians and gynaecologists · Source last updated April 2015 (third edition; first published April 2001 as GTG No. 28, second edition Feb 2007/reviewed 2010). No published RCOG update since 2015 as of this writing — clinicians should cross-check against current national VTE guidance for any interim changes.

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).